F 373280Alternative Names: F373280
Latest Information Update: 03 Nov 2016
At a glance
- Originator Pierre Fabre
- Class Antiarrhythmics; Esters
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Atrial fibrillation
Most Recent Events
- 20 Oct 2016 Pierre Fabre terminates a phase II trial in Atrial fibrillation in Poland, Spain, Italy, Hungary, Czech Republic (NCT01831856)